Your browser doesn't support javascript.
loading
Characterization of adverse cutaneous effects in the setting of enfortumab vedotin for metastatic urothelial carcinoma: A retrospective review.
Malik, Rhea; Xiang, David H; Riew, Grant J; Sanchez-Melendez, Stephanie; Afvari, Shawn; LeBoeuf, Nicole R; Nambudiri, Vinod E.
Afiliación
  • Malik R; Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Xiang DH; Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Riew GJ; Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Sanchez-Melendez S; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Ponce Health Sciences University, School of Medicine, Ponce, Puerto Rico.
  • Afvari S; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; New York Medical College, Valhalla, New York.
  • LeBoeuf NR; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Department of Cutaneous Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
  • Nambudiri VE; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Department of Cutaneous Oncology, Dana Farber Cancer Institute, Boston, Massachusetts. Electronic address: vnambudiri@bwh.harvard.edu.
J Am Acad Dermatol ; 2024 Jun 21.
Article en En | MEDLINE | ID: mdl-38909660

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Am Acad Dermatol Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Am Acad Dermatol Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos